Selank: Tuftsin Analog Research Overview

Selank is a synthetic heptapeptide analog of tuftsin, an endogenous peptide described in the literature for immunomodulatory activity. Like Semax, it carries a C-terminal Pro-Gly-Pro extension and was developed by the same Russian research lineage, which is why the two peptides appear together throughout the glyproline literature.

Molecular formula and molecular weight figures for Selank are widely quoted online but were not confirmed against a primary analytical source, so North Summit Labs does not state them. The independent lot-specific certificate is the authoritative record for the material you receive.

The mechanistic literature is preclinical. Kolomin and colleagues reported rodent hippocampal transcriptome studies examining how Selank and its fragments were associated with changes in expression of chemokine, cytokine, and receptor genes. Volkova and colleagues reported that Selank administration affected expression of several genes involved in GABAergic neurotransmission, and Filatova and colleagues extended that line of work in vitro using the human IMR-32 neuroblastoma cell line, comparing Selank with GABA itself and with olanzapine.

On the clinical side, two Russian-language psychiatric journal reports (Zozulya and colleagues in 2008; Medvedev and colleagues in 2015) describe intranasal Selank in patients diagnosed with generalized anxiety disorder or neurasthenia and report symptom-scale changes with proposed mechanisms.

The clinical reports are small open-label or observational studies published only in Russian-language journals; they are not large randomized controlled trials and no independent replication in the English-language literature was identified. No phase III randomized controlled trial for Selank was found.

The remaining work describes gene-expression associations in rodent tissue and in a neuroblastoma cell line. Gene-expression changes are not efficacy findings, and none of this literature establishes a mechanism of action with certainty in humans. This monograph reports what was studied, not what the compound does in people.

Selank is registered and marketed as a prescription nasal-drop product in Russia. It is not FDA-approved and has no approved medical use in the United States, the European Union, or most other jurisdictions. Drug-monitoring and forensic literature has also noted its appearance in unregulated preparations sold as research peptides, which is one reason lot-level analytical documentation matters for this compound.

Selank is supplied as a lyophilized powder in a sealed vial. Keep vials sealed and protected from moisture, heat, and light; allow cold material to equilibrate before opening; reconstitute with a solvent appropriate to the assay; and aliquot to avoid repeated freeze-thaw cycles. Record reconstitution date, solvent, and storage conditions alongside experimental results. See our laboratory storage guide for more detail.

Each Selank lot listed in our catalog is submitted to an independent analytical laboratory, and the resulting certificate reports identity and chromatographic purity for that specific lot. Published certificates are in the COA library, and the certificate matching the lot number on your vial is available on request.

This monograph summarizes published scientific literature for educational and reference purposes only. It is not medical, veterinary, clinical, or dosing guidance, and nothing here should be read as a claim that this compound is safe, effective, or approved for use in humans or animals.

Material supplied by North Summit Labs is intended strictly for in-vitro laboratory research by qualified professionals. It is not a drug, supplement, food, cosmetic, or medical device, and it is not for human or animal consumption. Investigators are responsible for complying with their own institutional oversight, biosafety, and legal requirements.